Browsing Modes for Business Users

EGF

ISO 9001 Quality Assurance Manufacturing | Print
No associated image currently available
No associated image currently available

Recombinant Human EGF

Product Type
Recombinant Protein
Specificity
EGF

Quick Links:

 Antibody Quality and Performance Guarantee
 Unrivaled Technical Support
Product Code Applications Pack Size List Price Your Price Qty
PHP030A
Datasheet Datasheet Datasheet
SDS Safety Datasheet SDS
E FN WB 0.5 mg
List Price Your Price

Recombinant human epidermal growth factor is 6.2kDa globular protein comprosed of 53 amino acids. EGF is a polypeptide growth factor which stimulates the proliferation of a wide range of epidermal and epithelial cells.

Target Species
Human
Species Cross-Reactivity
Target SpeciesCross Reactivity
Mouse
N.B. Antibody reactivity and working conditions may vary between species.
Product Form
Purified recombinant protein - lyophilized
Reconstitution
Reconstitute with 0.5ml distilled water
Care should be taken during reconstitution as the protein may appear as a film at the bottom of the vial. Bio-Rad recommend that the vial is gently mixed after reconstitution. For extended storage, the addition of 5% trehalose is recommended
Preparation
Purified recombinant human EGF expressed in E. coli
Source
E.coli
Preservative Stabilisers
None present
Carrier Free
Yes
Activity
1 x 107 units/mg
Purity
>98% by SDS PAGE and HPLC analysis
Approx. Protein Concentrations
1.0 mg/ml after reconstitution.
Protein Molecular Weight
6.2 kD (53 Amino acid sequence)
Endotoxin Level
< 0.1 ng/ug
Regulatory
For research purposes only
Guarantee
Guaranteed for 3 months from the date of reconstitution or until the date of expiry, whichever comes first. Please see label for expiry date.

Prior to reconstitution store at -20oC. Following reconstitution store at -20oC if preferred.

This product should be stored undiluted.

Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the protein. Should this product contain a precipitate we recommend microcentrifugation before use.

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
ELISA 0.2 0.4ng/well
Functional Assays 0.5 25ng/ml
Western Blotting 1.5 3.0ng/lane
Where this protein has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the protein for use in their own system using appropriate postive/negative controls.
ELISA
Recombinant human EGF may be used as athe standard in ELISA applications with either a purified human EGF antibody (AHP767) or a biotinylated human EGF antibody (AHP767B).
Western Blotting
Recombinant human EGF may be used as the positive control for Wester Blotting application with either a purified human EGF antibody (AHP767) or a biotinylated human EGF antibody (AHP767B)

References for EGF

  1. Tomlins, C. & Storey, A. (2010) Cutaneous HPV5 E6 causes increased expression of Osteoprotegerin and Interleukin 6 which contribute to evasion of UV-induced apoptosis.
    Carcinogenesis. 31 (12): 2155-64.
  2. Wray, H. et al. (2012) α6 Integrin and CD44 enrich for a primary keratinocyte population that displays resistance to UV-induced apoptosis.
    PLoS One. 7 (10): e46968.
  3. Chen, W. et al. (2016) Tissue Kallikrein Inhibitors Based on the Sunflower Trypsin Inhibitor Scaffold - A Potential Therapeutic Intervention for Skin Diseases.
    PLoS One. 11 (11): e0166268.
  4. Zhang, X. et al. (2015) Wnt signaling regulates the stemness of lung cancer stem cells and its inhibitors exert anticancer effect on lung cancer SPC-A1 cells.
    Med Oncol. 32 (4): 95.
  5. Roth, K. et al. (2021) Clinically relevant aberrant Filip1l DNA methylation detected in a murine model of cutaneous squamous cell carcinoma.
    EBioMedicine. 67: 103383.
  6. Inman, G.J. et al. (2018) The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature.
    Nat Commun. 9 (1): 3667.
  7. Aiderus, A. et al. (2021) Transposon mutagenesis identifies cooperating genetic drivers during keratinocyte transformation and cutaneous squamous cell carcinoma progression.
    PLoS Genet. 17 (8): e1009094.

Synonyms
Epidermal Growth Factor
UniProt
P01133
Entrez Gene
EGF
GO Terms
GO:0005886 plasma membrane
GO:0006260 DNA replication
GO:0005509 calcium ion binding
GO:0001525 angiogenesis
GO:0002576 platelet degranulation
GO:0016021 integral to membrane
GO:0005154 epidermal growth factor receptor binding
GO:0030297 transmembrane receptor protein tyrosine kinase activator activity
GO:0045741 positive regulation of epidermal growth factor receptor activity
GO:0007173 epidermal growth factor receptor signaling pathway
GO:0008083 growth factor activity
GO:0030168 platelet activation
GO:0031093 platelet alpha granule lumen
GO:0035413 positive regulation of catenin import into nucleus
GO:0042059 negative regulation of epidermal growth factor receptor signaling pathway
GO:0043406 positive regulation of MAP kinase activity
GO:0045840 positive regulation of mitosis
GO:0051048 negative regulation of secretion
GO:0090279 regulation of calcium ion import
GO:2000008 regulation of protein localization at cell surface

PHP030A

149919 162282

If you cannot find the batch/lot you are looking for please contact our technical support team for assistance.

View more products with EGF specificity

Please Note: All Products are "FOR RESEARCH PURPOSES ONLY"

View all Anti-Human Products
Please note